Session Title: Quick Fire Free Paper Session 03
Session Date/Time: Sunday 29/09/2013 | 08:30-09:30
Paper Time: 09:45
Venue: Hall C (Level 1)
First Author: N.Nugaeva RUSSIA
Co Author(s): E. Gileva T. Vasilieva T. Kamenskich E. Sumarokova
The aim of the work is to examine the preliminary results of the treatment of thrombosis, temporal branches of the central retinal vein, complicated cystic macular edema, including laser coagulation and intravitreal ranibizumab injection of the drug.
The main reason for the decline of visual function in retinal vein
The results of treatment of 50 patients with macular edema, thrombosis developed against the background of temporal branches of central vein of retina. First group included 25 patients In the treatment of patients in group I used laser coagulation and intravitreal injection of the drug ranibizumab. Group II included 25 patients All the patients I and II in the period from 1 to 6 months laser photocoagulation was performed in the pool area of the affected veins in areas of ischemia and impaired perfusion. To perform the procedure is used large spot size of 300-500 microns (depending on the distance from the macula). Order applied 750-1500 coagulates. Avoid areas hemorrhage to prevent lesions of the inner layers of the retina. Group I patients 1-2 weeks after laser coagulation intravitreal ranibizumab administered (Lucentis) in the amount of 0.05 ml from the standard procedure, with 3 injections at an interval of one month. Term monitoring of patients by 6 months after the injection.
The effectiveness of treatment was assessed by the dynamics of visual function, changes ophthalmoscopy, angiographic patterns and OCT data in group II after 2 months Laser coagulation in both groups, and in group I 2 months after the third injection of intravitreal ranibizumab. After two sessions LTGD by type ""grid"" was a positive trend. Visual acuity improved to 0.5. According to the results of OCT remained cystic swelling, limited in size, but with thinning of the upper wall of multiple cysts. Given the clinical picture, there have been the introduction of ranibizumab 0.05 mL in the vitreous. 7 days after surgery visual acuity of 0.9, on the OCT - the thickness and volume of the retina in the normal range, are stored cyst diameter of 15-20 mm. After the third injection of ranibizumab (infusion was performed at intervals of 1 month), visual acuity improved to 1.0. According to the OCT retinal thickness and volume in the normal range, structural changes have been identified. Stabilization of the process noted within 6 months of follow-up
1. A positive result of ranibizumab in combination with laser coagulation in patients with occlusions CVS branches. We evaluate these data as preliminary, requiring further research and refinement scheme of complex treatment of retinal vein thrombosis. 2. It should be noted that the safety functions of the macular region of the retina in patients with macular edema which developed against thrombosis temporal CVS branches, depending on the timeliness of adequate therapy. When the term of the disease for more than 8 months, despite the almost complete resorption of edema recovery of visual function occurs.